Description
Creon Micro - enteric granules of light brown color, from spherical to cylindrical shape.
Release form
Granules
Composition
Basis: Pancreatin Auxiliary substances: macrogol 4000 - 15.03 mg, hypromellose phthalate - 22.58 mg, cetyl alcohol - 0.48 mg, triethyl citrate - 1.25 mg, dimethicon 1000 - 0.54 mg.
Pharmacological effect
Enzyme agent. Contains pancreatic enzymes - amylase, lipase and proteases, which facilitate the digestion of carbohydrates, fats and proteins, which contributes to their more complete absorption in the small intestine. In diseases of the pancreas, it compensates for the insufficiency of its exocrine function and contributes to the improvement of the digestive process.
Indications
Insufficiency of the exocrine function of the pancreas (including chronic pancreatitis, cystic fibrosis). Chronic inflammatory and dystrophic diseases of the stomach, intestines, liver, gall bladder. conditions after resection or irradiation of these organs, accompanied by impaired food digestion, flatulence, diarrhea (as part of combination therapy). In order to improve food digestion in patients with normal gastrointestinal function in case of errors in nutrition, as well as violations of chewing function, forced by prolonged immobilization, sedentary lifestyle. Preparation for X-ray and ultrasound of the abdominal organs.
Contraindications
There are CONTRAINDICATIONS. BEFORE USE IT IS REQUIRED TO READ THE INSTRUCTIONS
Use during pregnancy and lactation
The safety of using pancreatin during pregnancy has not been studied enough. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus. In experimental studies, it was found that pancreatin does not have a teratogenic effect.
Dosage and administration
The dose (in terms of lipase) depends on the age and degree of pancreatic function insufficiency. The average dose for adults - 150 000 IU / day. With complete insufficiency of the excretory function of the pancreas - 400 000 IU / day, which corresponds to the daily need of an adult for lipase. The maximum daily dose is 15 000 U / kg. Children under 1.5 years old - 50 000 IU / day.older than 1.5 years - 100 000 IU / day. The duration of treatment can vary from several days (if the digestive process is disturbed due to errors in the diet) to several months or even years (if necessary, constant replacement therapy).
Side effects
When used in moderate therapeutic doses, side effects are observed in less than 1%.
From the digestive system: in some cases - diarrhea, constipation, feeling of discomfort in the stomach, nausea. The causal relationship between the development of these reactions and the action of pancreatin has not been established, since These phenomena are related to symptoms of exocrine pancreatic insufficiency.
Allergic reactions: in some cases - skin manifestations.
Metabolism: with prolonged use in high doses, hyperuricuricuria may develop, in excessively high doses, an increase in plasma uric acid levels.
Other: with the use of pancreatin in high doses in children, perianal irritation may occur.
Interaction with other drugs
With simultaneous use with antacids containing calcium carbonate and / or magnesium hydroxide, it is possible to reduce the effectiveness of pancreatin. With simultaneous use, it is theoretically possible to reduce the clinical efficacy of acarbose. With simultaneous use of iron preparations, iron absorption may be reduced.
special instructions
Use in children
The use is possible according to the dosing regimen. With a high activity of lipase contained in pancreatin, increases the likelihood of developing constipation in children.
special instructions
Not recommended for use in the acute phase of chronic pancreatitis.
In cystic fibrosis, the dose should be adequate to the amount of enzymes that are necessary for the absorption of fat, taking into account the quality and quantity of food consumed.
In cystic fibrosis, the use of pancreatin in doses of more than 10,000 U / kg / day (in terms of lipase) is not recommended due to the increased risk of stricture development (fibrous colonopathy) in the ileocecal region and in the ascending colon.
With a high activity of lipase contained in pancreatin, increases the likelihood of developing constipation in children. Increasing the dose of pancreatin in this category of patients should be carried out gradually.
Violations of the digestive system can occur in patients with hypersensitivity to pancreatin, or in patients with meconium ileus or a bowel resection in history.
Storage conditions
In a cool dry place. Keep out of the reach of children. Do not expose to direct sunlight. At room temperature
